Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Management changes at Seattle Genetics

This article was originally published in Scrip

Executive Summary

Bruce Seeley has been appointed executive vice-president of commercial at Seattle Genetics (US). He has more than 18 years' experience in oncology drug marketing and sales, having most recently served as senior director for Herceptin (trastuzumab) and T-DM1 marketing at Genentech (Roche). Seattle Genetics has also promoted its general counsel Kirk Schumacher to the additional role of vice-president of legal affairs and compliance.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC005077

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel